|1.||Besner, Gail E: 43 articles (07/2015 - 03/2002)|
|2.||Higashiyama, Shigeki: 25 articles (09/2014 - 01/2002)|
|3.||Mekada, Eisuke: 24 articles (05/2015 - 05/2003)|
|4.||Miyamoto, Shingo: 23 articles (08/2015 - 08/2004)|
|5.||Yotsumoto, Fusanori: 20 articles (08/2015 - 05/2006)|
|6.||Kuroki, Masahide: 14 articles (08/2015 - 11/2007)|
|7.||Chen, Chun-Liang: 11 articles (06/2014 - 04/2010)|
|8.||Yagi, Hiroshi: 10 articles (08/2014 - 08/2004)|
|9.||Radulescu, Andrei: 10 articles (01/2013 - 08/2007)|
|10.||Yu, Fu-Shin X: 10 articles (11/2011 - 03/2004)|
11/01/2005 - "Heparin-binding, EGF-like growth factor protected the intestine from injury when administered before injury and was also effective when administered during ischemia or even after injury. "
06/01/2014 - "In the current study, we investigated whether the ability of HB-EGF to protect the intestines from ischemia/reperfusion (I/R) injury was related to its effects on Wnt/β-catenin signaling in intestinal stem cells (ISC). "
09/01/2010 - "In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). "
06/01/2008 - "The aim of the current study was to evaluate the effect of HB-EGF gene disruption on intestinal restitution, angiogenesis, and long-term survival after intestinal ischemia/reperfusion (I/R) injury. "
05/01/1997 - "Immunohistochemical studies revealed that HB-EGF was produced predominantly in distal tubules in kidneys injured either by ischemia/reperfusion or aminoglycoside administration. "
09/01/2013 - "Studies show that HB-EGF expression is essential in oncogenesis of cancer-derived cell lines. "
06/10/2012 - "In the present study, we developed novel immunoliposomes targeting HB-EGF for cancer therapy. "
02/01/2010 - "This study not only associates Tgf-α and Hb-egf expression with wild-type Egfr oncogenicity but also ascribes the proangiogenic activity of Egfr in this tumor model to a novel mesenchymal Hb-egf/Egfr signaling axis, whereby endothelial and pericyte-derived Hb-egf activates Egfr specifically in tumor-associated perivascular cells, leading to increased pericyte coverage of the tumor endothelium and enhanced angiogenesis."
05/01/2006 - "Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. "
08/01/2004 - "In vivo studies also demonstrated that tumor cells expressing s-HB-EGF or wild-type HB-EGF significantly enhanced tumorigenic potential in athymic nude mice and exerted an angiogenic effect, increasing the density and size of tumor blood vessels. "
|3.||Wounds and Injuries (Trauma)
11/01/2010 - "The wound closure was significantly impaired in HB(-/-) MCECs and was improved by adding HB-EGF. "
07/01/2015 - "The multifunctional role of HB-EGF in the healing process and its enhanced efficacy when delivered by the coacervate make it a promising therapy for diabetic wounds. "
06/01/2005 - "Studies of wound healing revealed that wound closure was markedly impaired in keratinocyte-specific HB-EGF-deficient mice. "
07/01/2015 - "In full-thickness excisional wounds on NONcNZO10 diabetic mice, HB-EGF coacervate enhanced the proliferation and migration of epidermal keratinocytes, leading to accelerated epithelialization. "
07/01/2015 - "Coacervate delivery of HB-EGF accelerates healing of type 2 diabetic wounds."
07/01/1998 - "Finally, HB-EGF-treated cells had a significantly improved proliferative ability compared with nontreated cells during recovery from hypoxia (P < .05). "
05/01/2013 - "We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. "
04/15/2013 - "Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia."
10/01/2012 - "HB-EGF significantly protected AF-MSCs and BM-MSCs from anoxia-induced apoptosis. "
01/01/2012 - "In addition, HB-EGF protected pericyte-like cells from anoxia-induced apoptosis. "
01/01/2005 - "These results indicate that expression of HB-EGF and generation of its soluble form, followed by activation of EGFR and ErbB2, are pivotal processes in tRA-induced epidermal hyperplasia."
01/01/2005 - "tRA-induced epidermal hyperplasia was reduced both in the keratinocyte-specific HB-EGF null mice (K5-HB(del/del)) and knock-in mice expressing the uncleavable mutant form of HB-EGF (HB(uc/uc)), as compared with wild-type HB-EGF knock-in mice (HB(lox/lox)). "
01/01/2005 - "HB-EGF is normally expressed in epidermis of normal adult mice at very low levels, but topical tRA treatment results in epidermal hyperplasia, concomitant with the strong induction of HB-EGF expression in the suprabasal layer. "
12/01/2001 - "Further, it was shown that an antibody to HB-EGF-like growth factor inhibited retinoid-stimulated epidermal hyperplasia in organ culture and reduced proliferation in cultured keratinocytes. "
12/01/1998 - "These results support the hypothesis that the effects of RA on epidermal hyperplasia are mediated at least in part by HB-EGF, and suggest that signal transduction mechanisms other than or in addition to nuclear RA receptors contribute to this effect."
|1.||Epidermal Growth Factor (EGF)
|3.||Messenger RNA (mRNA)
|4.||CRM197 (non-toxic variant of diphtheria toxin)
|5.||Galectin 1 (LGALS1)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||tyrphostin AG 1478
|4.||Heterologous Transplantation (Xenotransplantation)